오스코텍

039200KOSDAQ의약품 제조업

57.8 / 100

Reference Date: 2026-06-10

Financial Score22.0 / 40

News Sentiment19.8 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 19.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Oskotech is a research-focused biopharmaceutical company specializing in new drug development, functional materials, and dental bone grafts. It is currently conducting clinical trials for two synthetic drug candidates and holds a targeted anti-cancer drug approved by the US FDA. Major revenue streams come from technology transfer milestones and royalty income.

Number of Employees

57people

Average Salary

61.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

28.80Industry Average 11.930.0Point

2.4x industry avg (risky)

PBR

8.07Industry Average 0.890.0Point

9.1x industry avg (risky)

ROE

34.08Industry Average 4.017.0Point

8.5x industry avg (excellent)

Debt Ratio

2.16Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲390.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲1048.3% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.1% (improving, 3yr)

Detailed News Sentiment

20 totalPositive 17Neutral 3Negative 0Average Sentiment Score 79

Positive
'창업주 별세' 오스코텍, 경영 개선 구원투수로 라데팡스 참여
라데팡스파트너스의 참여로 오스코텍의 지배구조 개선이 예상되어 경영 안정화에 긍정적 영향이 기대됩니다.
Neutral
창업주 별세 후 혼란한 오스코텍, 라데팡스파트너스가 구원투수로
Oscotech faces governance challenges post-CEO's passing; new partnership aims to stabilize operations.
Positive
바이오, 상반기 기술수출 13조…다음 타자 누구?
오스코텍의 기술 수출 규모 증가로 K-바이오 분야의 신약 기술이 주목받고 있다.

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 39,400Won52-week high 62,00052-week low 27,250

1-month return0.0Point

1m -19.76% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral투자판단관련주요경영사항 (SYK 저해제 후보물질 세비도플레닙(SKIO703) 기술수출 계약 체결)2026-06-01
Neutral주식등의대량보유상황보고서(약식)2026-05-29
Neutral주식등의대량보유상황보고서(약식)2026-05-22
Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (SKIO703의 약물 제형 변경을 위한 임상 1상 IND 승인)2026-05-22
Neutral기업설명회(IR)개최2026-05-14